This is a monocentric, randomized, opened study to assess the anti-inflammatory and anti-platelet effect of Clopidogrel and aspirin versus aspirin or clopidogrel alone in patients with symptomatic polyvascular disease and with multiple recurrent cardiovascular events.

Inclusion Criteria:

• Patients with symptomatic polyvascular disease or recurrent cardiovascular events. In particular patients with established stable coronary artery disease associated with peripheral disease or cerebrovascular disease and patients with more than two acute cardiovascular events.

Exclusion Criteria:

• chronic treatment with anticoagulant drugs and the use of other antiplatelet therapy;
• intolerance/allergy to Aspirin or to Clopidogrel
• platelet counts outside the range of 125-450 10^9/l
• inflammatory or infectious disease
• malignancies or immunologic or hematological disorders.